Midamor (Amiloride) Drug Information: Clinical Pharmacology

Pill Identifier Search

May 27, 2012

Midamor

High Blood Pressure »

High blood pressure facts

High blood pressure (hypertension) is designated as either essential (primary) hypertension or secondary hypertension and is defined as a consistently elevated blood pressure exceeding 140/90 mm Hg.
High blood pressure is called "the silent killer" because it often causes no symptoms for many years, even decades, until it finally damages certain critical organs.
Poorly controlled high blood pressure ultimately can cause damage to blood vessels in the eye, thickening of the heart muscle and heart attacks, hardening of the arteries (arteriosclerosis), kidney failure, and strokes.
Most antihypertensive medications can be used alone or in combination. Some are used only in combination. Some are preferred over others in certain specific medical situations. And some are not to be used (contraindicated) in other situations.
Several classes of antihypertensive medications are available, including ACE i...

Read the High Blood Pressure article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Midamor

High Blood Pressure (Hypertension) Slideshow

Take the Salt Quiz!

Lowering Blood Pressure Exercise Tips Pictures

font size

Please Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

CLINICAL PHARMACOLOGY

MIDAMOR (amiloride) is a potassium-conserving (antikaliuretic) drug that possesses weak (compared with thiazide diuretics) natriuretic, diuretic, and antihypertensive activity. These effects have been partially additive to the effects of thiazide diuretics in some clinical studies. When administered with a thiazide or loop diuretic, MIDAMOR (amiloride) has been shown to decrease the enhanced urinary excretion of magnesium which occurs when a thiazide or loop diuretic is used alone. MIDAMOR (amiloride) has potassium-conserving activity in patients receiving kaliuretic-diuretic agents.

MIDAMOR (amiloride) is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone.

MIDAMOR (amiloride) exerts its potassium sparing effect through the inhibition of sodium reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct; this decreases the net negative potential of the tubular lumen and reduces both potassium and hydrogen secretion and their subsequent excretion. This mechanism accounts in large proof for the potassium sparing action of amiloride.

MIDAMOR (amiloride) usually begins to act within 2 hours after an oral dose. Its effect on electrolyte excretion reaches a peak between 6 and 10 hours and lasts about 24 hours. Peak plasma levels are obtained in 3 to 4 hours and the plasma half-life varies from 6 to 9 hours. Effects on electrolytes increase with single doses of amiloride HCl up to approximately 15 mg.

Amiloride HCI is not metabolized by the liver but is excreted unchanged by the kidneys. About 50 percent of a 20 mg dose of MIDAMOR (amiloride) is excreted in the urine and 40 percent in the stool within 72 hours. MIDAMOR (amiloride) has little effect on glomerular filtration rate or renal blood flow. Because amiloride HCl is not metabolized by the liver, drug accumulation is not anticipated in patients with hepatic dysfunction, but accumulation can occur if the hepatorenal syndrome develops.

Last reviewed on RxList: 5/19/2008
This monograph has been modified to include the generic and brand name in many instances.